Antares Pharma Partner Pfizer Achieved Development Milestone (ATRS, PFE)
10/04/2012

[Antares Pharma, Inc. focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines]

Online PR News – 04-October-2012 – Las Vegas, NV – Antares Pharma, Inc. (NASDAQ: ATRS) Pfizer Inc. (NYSE: PFE) ATRS recently reported that its partner PFE achieved a development milestone related to its undisclosed Consumer Healthcare product. This development milestone in Antares’ collaboration with Pfizer triggers a $750,000 payment to Antares. In December of 2011, Antares licensed to Pfizer’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer has assumed full cost and responsibility for all clinical development, manufacturing and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. Antares received an upfront payment, and will receive development and sales based milestones, as well as royalties on net sales for three years post launch in the U.S. Antares Pharma, Inc. (NASDAQ: ATRS) focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company's technology platforms include VIBEX™ disposable Medi-Jet, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH), VIBEX epinephrine and several other products. Antares Pharma’s partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for overactive bladder that is marketed by Watson Pharmaceuticals, Inc. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted VIBEX Medi-Jet and pen injector systems. The Company’s corporate head office and Product Development Group are located in Ewing, New Jersey. For more information about Antares Pharma, Inc. visit www.antarespharma.com. Pfizer Inc. (NYSE: PFE), a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. It primarily offers Celebrex, Chantix/Champix, Lipitor, Lyrica, Premarin, Pristiq, and Viagra pharmaceutical products in the therapeutic and disease areas of Alzheimer?s disease, cardiovascular, erectile dysfunction, genitourinary, depressive disorder, pain, respiratory, and smoking cessation. For more information about Pfizer Inc. visit www.pfizer.com.

Crown Equity Holdings Inc. (CRWE) CRWE AD-Services, a division of CRWE is a full service multimedia advertising company specializing in internet marketing. Their goal is to provide you with a customized advertising blue print using their expansive resources. CRWE Ad Services (www.crwe-adservices.com ) provides modern and unique advertising campaigns. They are dedicated to offering the most cost effective advertising solutions. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: CRWEWallStreet.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://crwewallstreet.com/disclaimer).